 Carlyle Group LP is close to acquiring Johnson & Johnson's blood-testing business for around $4 billion, said people familiar with the matter, in a deal that could be announced this week.. The Washington, D.C.-based private-equity firm is expected to pay between $4 billion and $4.2 billion for the business, which makes tests that can reveal a patient's blood type and screen for viruses such as HIV and hepatitis C, the people said. A deal could be announced as soon as Thursday, they said. The people cautioned the deal's...
  